Arturo Giordano

Arturo Giordano

Auto-generated profile, based on publicly available information

Arturo Giordano

Pineta Grande Hospital

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
GFGermano Junior Ferruzzi
Germano Junior Ferruzzi
Angelo SilverioAngelo Silverio
Angelo Silverio
AGArturo Giordano
Arturo Giordano
NCNicola Corcione
Nicola Corcione
MBMichele Bellino
Michele Bellino
Gennaro GalassoGennaro Galasso
Gennaro Galasso
Background: There is little evidence about the prognostic role of mitral regurgitation (MR) in patients with low‐flow, low‐gradient aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). The aim of this study was to assess the prevalence and outcome implications of MR severity in patients with low‐flow, low‐gradient aortic stenosis undergoing TAVR, and to evaluate whether MR improvement after TAVR could influence clinical outcome. Methods and Results: This study included consecutive patients with low‐flow, low‐gradient aortic stenosis undergoing TAVR at 2 Italian high‐volume centers. The study population was categorized according to the baseline MR severity and to the presence of MR improvement at discharge. The primary outcome was the composite of all‐cause death and hospitalization for worsening heart failure up to 1 year. The study included 268 patients; 57 (21%) patients showed MR >2+. Patients with MR >2+ showed a lower 1‐year survival free from the primary outcome ( P <0.001), all‐cause death ( P <0.001), and heart failure hospitalization ( P 2+ was an independent predictor of the primary outcome ( P 2+, MR improvement was reported in 24 (44%) cases after TAVR. The persistence of MR was associated with a significantly reduced survival free from the primary outcome, all‐cause death, and heart failure hospitalization up to 1 year. Conclusions: In this study, the presence of moderately severe to severe MR in patients with low‐flow, low‐gradient aortic stenosis undergoing TAVR portends a worse clinical outcome at 1 year. TAVR may improve MR severity in nearly half of the patients, resulting in a potential outcome benefit after discharge.

1 August 2011 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
AGArturo Giordano
Arturo Giordano
ARAlfredo Romano
Alfredo Romano

1 December 2019 in Minerva Cardiology and Angiology
Verified
Journal Article
Closed access
AGArturo Giordano
Arturo Giordano
OIon behalf of the Registro Italiano GISE sull'impianto di Valvola Aortica Percutanea (RISPEVA) Study Investigators
on behalf of the Registro Italiano GISE sull'impianto di Valvola Aortica Percutanea (RISPEVA) Study Investigators
NCNicola Corcione
Nicola Corcione
PFPaolo Ferraro
Paolo Ferraro
AMAlberto Morello
Alberto Morello
Giuseppe Biondi-ZoccaiGiuseppe Biondi-Zoccai
Giuseppe Biondi-Zoccai
Expanding indications to transcatheter aortic valve implantation (TAVI) warrant meticolous vascular management and minimization of access site complications. Two leading vascular closure devices (VCD) are currently used for TAVI, ProGlide vs. Prostar, but their comparative effectiveness and safety are debated. We aimed at comparing acute and 1-month outcomes of patients undergoing TAVI using as VCD either ProGlide (Perclose) or Prostar (XL). The prospective RISPEVA database was queried for baseline, procedural, and outcome details of patients undergoing TAVI and in whom either ProGlide or Prostar had been used as VCD. Outcomes of interest were death, vascular complication, and bleeding, distinguishing specific subtypes. Outcomes were adjudicated according to current Valve Academic Research Consortium definitions. A total of 1987 subjects were included, 913 (46.0%) receiving ProGlide, and 1074 receiving Prostar (54.0%). Several baseline and procedural differences were evident, including surgical risk, concomitant coronary artery disease, sheath size, use of predilation, and chosen TAVI device (all P<0.05). Periprocedurally, despite similar rates of device success (P=0.262), Prostar was associated with a lower risk of vascular stenosis (P=0.005), but a higher rate of device malfunction (P=0.028). Unadjusted analysis for 1-month outcomes suggested higher rates of major adverse events, any bleeding, major bleeding, and renal failure in patients receiving Prostar (all P<0.05). However, propensity score-adjusted analysis did not confirm any significant differences, suggesting that confounding factors mostly drove unadjusted differences. Use of ProGlide and Prostar as VCD of choice for TAVI appears similarly safe and effective, despite some potential benefits associated with ProGlide. Further randomized trials are warranted to confirm or disprove these findings.

1 October 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
AGArturo Giordano
Arturo Giordano
NCNicola Corcione
Nicola Corcione
MPMichele Polimeno
Michele Polimeno
SMStefano Messina
Stefano Messina
Giuseppe Biondi-ZoccaiGiuseppe Biondi-Zoccai
Giuseppe Biondi-Zoccai
PFPaolo Ferraro
Paolo Ferraro

1 January 2014 in International Journal of Surgery Case Reports
Verified
Journal Article
Open access
PPPaolo Pepino
Paolo Pepino
GCGermano Coronella
Germano Coronella
POPiermario Oliviero
Piermario Oliviero
MMMario Monaco
Mario Monaco
VSVincenzo Schiavone
Vincenzo Schiavone
AGArturo Giordano
Arturo Giordano
INTRODUCTION: Surgical coronary revascularization is being performed with ever increasing frequency in patients at high surgical risk. Off-pump coronary artery bypass grafting (OPCABG) is particularly appealing in such subjects, but may limit the options for concomitant mechanical circulatory support. PRESENTATION OF CASE: We hereby report an original case of mechanical circulatory support with the Impella Recover LP 5.0 device during OPCABG in a 61-year-old gentleman with multiple comorbidities and severe left ventricular systolic dysfunction. Specifically, the soft tipped device did not impede surgical manipulation of the heart during the surgical procedure, providing uninterrupted circulatory support to the patient. DISCUSSION: This clinical vignette supports the feasibility, safety and efficacy of the Impella Recover LP 5.0 device in patients undergoing OPCABG. CONCLUSION: Pending further studies, use of the Impella Recover LP 5.0 device can be envisioned safely for OPCABG.

21 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
AGArturo Giordano
Arturo Giordano
PFPaolo Ferraro
Paolo Ferraro
FFFilippo Finizio
Filippo Finizio
NCNicola Corcione
Nicola Corcione
MCMichele Cimmino
Michele Cimmino
FBFrancesco Bedogni
Francesco Bedogni
Background: Minimally invasive mitral valve repair has a favorable risk–benefit profile in patients with significant de novo mitral regurgitation. Its role in patients with prior mitral valve repair is uncertain. We aimed to appraise the outcome of patients undergoing transcatheter edge‐to‐edge repair (TEER) with prior transcatheter or surgical mitral valve repair (SMVR). Methods and Results: We queried the Italian multicenter registry on TEER with MitraClip, distinguishing naïve patients from those with prior TEER or (SMVR). Inhospital and long‐term clinical/echocardiographic outcomes were appraised. The primary outcome was the occurrence of death or rehospitalization for heart failure. A total of 2238 patients were included, with 2169 (96.9%) who were naïve to any mitral intervention, 29 (1.3%) with prior TEER, and 40 (1.8%) with prior SMVR. Several significant differences were found in baseline clinical and imaging features. Respectively, device success was obtained in 2120 (97.7%), 28 (96.6%), and 38 (95.0%, P =0.261) patients; procedural success in 2080 (95.9%), 25 (86.2%), and 38 (95.0%; P =0.047); and inhospital death in 61 (2.8%), 1 (3.5%), and no ( P =0.558) patients. Clinical follow‐up after a mean of 14 months showed similar rates of death, cardiac death, rehospitalization, rehospitalization for heart failure, and their composite (all P >0.05). Propensity score–adjusted analysis confirmed unadjusted analysis, with lower procedural success for the prior TEER group (odds ratio, 0.28 [95% CI, 0.09–0.81]; P =0.019) but similar odds ratios and hazard ratios for all other outcomes in the naïve, TEER, and SMVR groups (all P >0.05). Conclusions: In carefully selected patients, TEER can be performed using the MitraClip device even after prior TEER or SMVR.